SlideShare uma empresa Scribd logo
1 de 41
The R&D Cost of a New Medicine
Jorge Mestre-Ferrandiz
Office of Health Economics
University College London • VISION Seminar
London • 29 January 2013
The R&D Cost of a New Medicine
Download or
read online at
www.ohe.org
2
The R&D Cost of a New Medicine
1. Up to date overview of the literature estimating
pharmaceutical R&D costs and the factors driving them
2. Present a new estimate from original data of the
average R&D cost per new successful medicine
Objectives of the OHE Study
3
The R&D Cost of a New Medicine
Structure of the Book
4
Factors driving R&D costs
Mean cost of an NME
(S2 & S3)
Development times
(S2.4)
Out-of-pocket costs
(S2.2)
Success rates
(S2.3)
Cost of capital
(S2.5)
Explaining differences from the mean
Therapy areas
(S4)
Compound origin
(S5)
Firm size
(S6)
Biologicals
(S7)
Drivers of Trends in R&D Costs (S8)
The R&D Cost of a New Medicine
• Published estimates of the mean (average) cost of R&D per
new medicine that is launched on the market suggest an
increase in cost over the last decade -- from the estimate
of US$1.0bn (£600m) by DiMasi et al. (2003), expressed in
2011 price terms, to US$1.9bn (£1.2bn) by Paul et al. 2010)
• Our new estimate is US$1.5bn (£900m) and therefore lies
between the DiMasi and Paul estimates
• Estimates of mean R&D costs per new medicine, and
comparisons between such estimates, must be treated
with caution: studies differ in both methodology and data
used
Key Findings
5
The R&D Cost of a New Medicine
• How much it costs to research and develop a successful
new medicine has been an important policy issue at
least since the 1960s
• Cost estimates matter not just because of intellectual
curiosity or for industry understanding of its
performance, but because they are a key aspect of the
international debate about the reasonableness of
pharmaceutical prices and the magnitude of the long-
term investments involved
• Moreover, a related debate continues about whether the
research and development (R&D) productivity of the
biopharmaceutical industry has fallen
Context
6
The R&D Cost of a New Medicine
7
REGULATION
TIME (YEARS)
PHASES OF
DRUG
DEVELOPMENT
Phase III
Development research
Final patent
application
Marketing
application
Post-mktg
research*
Phase
IV
2002-7
Discovery research
Investigational new
drug application (US)
1999
Phase I Phase IISynthesis
Biological testing &
pharmacologic
screening
2008
Marketing
approval/
product launch
2010
Regulatory
review
Basic
research
Short-term animal testing
Long-term animal testing
Toxicology and pharmacokinetic studies
Chemical development
Pharmaceutical development
Fig 2.1. The R&D Process
*Phase IV is not part of the R&D process, although data collected during that time may affect how the drug is used.
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics
The R&D Cost of a New Medicine
Key Studies
8
The R&D Cost of a New Medicine
Key Studies
9
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
The R&D Cost of a New Medicine
• Four main variables determine the capitalised
cost of a new drug estimate
• Out-of-pocket costs
• Success rates
• Development times and
• Cost of capital
Key Components of R&D Costs
10
The R&D Cost of a New Medicine
Out-of-pocket costs
• Out-of-pocket
development
costs, before
adjusting for
failures, appear
to have increased
over time. Similar
estimates for
total out-of-
pocket devel-
opment costs but
less consistent
across clinical
trial phases
Success rates
• Cumulative
clinical success
rates appear to
have decreased
over time. The
probability is
shrinking that a
candidate
entering Phase I
clinical trials will
in due course be
authorised to be
launched onto
the market
Development times
• The total time
taken to progress
through all
phases of clinical
trials and market
authorisation
appears to have
remained rela-
tively unchanged
since the early
2000s
Cost of capital
• The long time-
scales of pharma-
ceutical R&D
mean that the
cost of capital has
a major impact
on the final cost
per drug and so
the estimated
development cost
per successful
drug is highly
sensitive to the
cost of capital
applied. An 11%
real annual cost is
commonly used.
Key Components of R&D Costs
11
The R&D Cost of a New Medicine
• Out-of-pocket development costs, before adjusting for
failures, appear to have increased over time since the
first DiMasi et al. (1991) article
• The most recent estimates, by Paul et al. (2010) and
Adams and Brantner (2010), are very similar for out-of-
pocket development costs (from Phase I to III) at around
US$215-220m (2011 US$)
• The studies are less consistent in their estimates of the
magnitude of the cost of the different clinical trial phases
Out-of-Pocket Costs
12
The R&D Cost of a New Medicine
Out-of-Pocket Costs
13
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
The R&D Cost of a New Medicine
• The most recent estimates of probability of success
for Phase I, Phase II and Phase III are between 49%
and 75%, 30% and 48%, and 50% and 71%,
respectively
• Overall, cumulative clinical success rates appear to
have decreased over time
• Pammolli et al. (2011) find significant decreases in
success rates, especially in Phases II and III
• But analyses by DiMasi and colleagues since the early
1990s suggest that success rates across the different
phases have changed little
Success Rates
14
The R&D Cost of a New Medicine
Success Rates
15
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
The R&D Cost of a New Medicine
• Commercial reasons have been increasingly important
for discontinuing projects
• Since 2000, companies have been focusing more on high
risk, high premium areas with a lower “expected
probability of success” (POS), such as:
• Chronic diseases (Alzheimer’s disease, diabetes, obesity,
rheumatoid arthritis) compared to acute diseases (6.9% vs
8.8%)
• Potentially lethal diseases, mostly cancer and some
infectious diseases (5.5% vs. 9.7%) [Pammolli, Magazzini and
Riccaboni (2011)]
Attrition Rates: Reasons for Failure
16
The R&D Cost of a New Medicine
• Overall, development times (Phases I-III) appear to have
remained relatively constant over time, at around 6.5
years (75‒79 months) on average. Phase III trials tend to
be the longest development phase, although the most
recent work suggests that development times for Phases
II and III now are similar
Development Times
17
The R&D Cost of a New Medicine
Development Times
18
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
The R&D Cost of a New Medicine
• The long timescales of pharmaceutical R&D mean that
the cost of capital has a major impact on the final cost
per successful drug
• The cost of capital should be measured as the expected
return that is foregone, i.e. the return that would be
expected from investing in an equally risky portfolio of
other investments
• The estimated cost per successful drug is highly sensitive
to the cost of capital applied
• The more recent studies use a real annual cost of capital
of 11%, up from the 9% used by DiMasi et al. (1991)
Cost of Capital
19
The R&D Cost of a New Medicine
• Two main issues arise with respect to the cost of
capital invested in pharmaceutical R&D
• The magnitude of the cost of capital
• Whether the cost of capital is assumed constant or
instead is assumed to fall as an R&D project progresses
(if successful) through its various stages from discovery
through development to launch – the so-called “staircase”
approach
Cost of Capital
20
The R&D Cost of a New Medicine
Cost of Capital
21
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
The R&D Cost of a New Medicine
Criticisms OHE Book
Data – confidential, comes from companies
directly and cannot be replicated
Other recent studies have either used publicly
available information or have used different
confidential data (like ours)
Only self-originated compounds are included and
these represent a small proportion of new drugs –
and the most expensive ones
Decreasing importance of self-originated
compounds relative to licensed-in compounds is
valid, but has become so perhaps only recently.
More recent estimates cannot differentiate so
apply also to a wider universe of compounds, not
just self-originated compounds
Estimates should not be capitalised, given that
companies are not investment houses and have no
choice but to spend money on R&D
Out-of-pocket costs are merely one part of the
total cost. Capitalised costs are real costs.
Investors require a return that reflects alternative
potential uses of their investment
Estimates are pre-tax, so they do not reflect the
fact that R&D expenses are deductible
Societal perspective when thinking about the costs
of R&D of new medicines: total cost of developing
a new drug will be the same no matter who pays --
tax rebates affect who bears the costs, but not the
total amount
Policy Discussions Around the Cost Estimates
22
The R&D Cost of a New Medicine
• New estimate for mean R&D costs per NME, based on
previously unpublished information collected by CMRI in
confidential surveys
A New Estimate of R&D Costs
23
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
The R&D Cost of a New Medicine 24
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
The R&D Cost of a New Medicine 25
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
The R&D Cost of a New Medicine 26
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A.
(2012) The R&D Cost of a New Medicine. London: Office
of Health Economics.
The R&D Cost of a New Medicine 27
Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
The R&D Cost of a New Medicine
• Our overall probability of success estimates for Phase I, Phase II
and Phase III are lower than those reported by DiMasi et al. (2003)
and Paul et al. (2010)
• Overall, our study and those by DiMasi et al. (2003) and Paul et al.
(2010) report similar development times. For Phase I, our data
report the longest development times, but slightly shorter times for
Phase III. Phase II times from the CMRI data fall between those
reported by DiMasi et al. (2003) and Paul et al. (2010)
• Total out-of-pockets costs for Phases I, II and III are very similar in
our study and that of Paul et al. (around US$230m at 2011 prices)
and slightly lower than found by DiMasi et al (2003). Our out-of-
pocket cost estimate lies between the other two estimates for
Phase III. For Phase I and Phase II, our estimates are the highest
Comparison with Previous Studies
28
The R&D Cost of a New Medicine
• Published estimates, including ours, that refer to the
mean cost of R&D per new medicine are just that:
averages
• The literature shows that the costs of R&D vary with
the subgroup of drugs included in the analysis
• Costs vary according to therapeutic area, firm size
and whether the molecule is a “traditional” chemical
compound or a biologic
Warning: Mean Costs May Hide Important Differences
29
The R&D Cost of a New Medicine
• R&D costs vary substantially across therapeutic areas
because of considerable variation in three key variables:
success rates, development cycle times and out-of-
pocket costs.
• The most recent analyses suggest that the most expensive
therapeutic areas in terms of drug R&D costs are
neurology, respiratory and oncology. This is because drugs
in these categories experience lower success rates and
longer development times.
• By comparison, anti-parasitics and drugs to treat HIV/AIDS
have the lowest drug R&D costs because of higher success
rates and shorter development times
Therapeutic Areas
30
The R&D Cost of a New Medicine
• Most of the published calculations of R&D costs to
date focus on self-originated new compounds
because comprehensive data for licensed-
in/acquired compounds are very difficult to collect
• An increasing proportion of drugs now are licensed
in; clinical success rates for such drugs are higher
than for self-originated drugs
Self-Originated versus Licensed-In
31
The R&D Cost of a New Medicine
• Greater success may be the results of a “screening
effect” for licensed-in compounds:
• Many licensed-in drugs already were shown to be
promising candidates before licensing
• This difference also is apparent during early research
Self-Originated versus Licensed-In
32
The R&D Cost of a New Medicine
• Limited evidence on biological medicines
• DiMasi and Grabowski (2007b): overall clinical success rate for
biotech products is 30.2%, which is higher than the 21.5%
estimate for traditional pharmaceutical products reported by
DiMasi et al. (2003)
• Total clinical and approval time is 8% longer for biopharma-
ceuticals, with nearly all the difference being in Phase I
• Capitalisation increases biopharma costs relative to traditional
R&D costs because of the longer development timeline and a
slightly higher cost of capital
Biopharmaceuticals
33
The R&D Cost of a New Medicine
• Cost of clinical trials
• Cost per patient and number of patients
• Complexity
• Two trends appearing to help control costs
• Outsourcing to CROs – increased efficiency
• Change in location
• Some trials in emerging markets – lower local costs and faster
patient recruitment
• Still significant proportion of trails located in US and Western
Europe – regulatory conditions, relevant expertise and
infrastructure
Drivers of Trends – Out-of-Pocket Costs
34
The R&D Cost of a New Medicine
Increase in
failure rates
• Regulators becoming more risk averse
• R&D is directed towards tougher challenges
• Within companies, projects may advance prematurely to the later
stages of clinical development and then fail in Phase III
Reasons to
counter
increase
• Better preclinical screening that ensures earlier project termination
• Integrating HTA earlier in the process to encourage earlier decisions
about discontinuing projects for commercial reasons
• Developing biomarkers and companion diagnostics that can lead to
personalised or stratified medicine, with greater prospects for
success
• Alliances between companies, increasingly common, also may
increase success rates
Drivers of Trends – Failure Rates
35
In short run important technological challenges may lead to higher failure rates and costs as
science advances and while companies learn how to better develop biomarkers and
companion diagnostics.
But “learning by doing” could drive a more efficient R&D process in the longer term.
The R&D Cost of a New Medicine
• Regulators may be more risk averse, leading to increased
regulatory stringency and longer regulatory reviews
• Companies are directing efforts towards therapeutic
areas that intrinsically are associated with very long
clinical development times
• Clinical trials are becoming increasingly complex and, as
a result, take longer to complete
• Trade offs between time and success rate, e.g. longer
Phase II with higher success rate in Phase III
Drivers of Trends – Development Times
36
The R&D Cost of a New Medicine
• Number of alternatives have been put forward to try
to make the R&D process more efficient and
affordable
• The key suggestions include focusing on
• The earlier phases reduce technical uncertainties before
undertaking the more expensive trials in the later
development stages
• Allowing for greater flexibility
A New Drug Development Paradigm?
37
The R&D Cost of a New Medicine
Four factors are increasing R&D costs:
1. Higher out-of-pocket costs, up nearly 600% from the 1970s
to the 2000s
2. Lower success rates for clinical development as tougher
therapeutic areas are tackled—e.g. neurology (Alzheimer’s),
autoimmune diseases (arthritis), and oncology—from 1 in 5
in the 1980s to 1 in 10 in the 2000s
3. Increases in R&D times as both regulation and science have
become more complex, from 6 years in the 1970s to 13.5
years in the 2000s
4. Increases in the cost of capital—i.e. providing returns to
funders that reflect the high risk of investing in medicines
R&D—from 8% in the 1970s to 11% in the 2000s
Conclusions
38
The R&D Cost of a New Medicine
• Important variations around the mean cost per NME for
different types of medicines are observable
• Significant differences are evident in the cost of R&D for new
medicines across therapeutic areas – can be more than
twofold
• Licensed-in compounds tend to be more successful than self-
originated NMEs
• Drugs with a more validated target and more objective
endpoints are more successful than drugs with more novel
mechanisms of action and less clear cut endpoints
• Total capitalised costs for biologics appear to be higher than
for other pharmaceuticals
Conclusions
39
The R&D Cost of a New Medicine
Technological challenges
•Targeted diseases currently are
more complex
•Companies need to adapt to
new personalised/stratified
medicines environment
Firms’ behaviour
•Companies continue to work
to improve the efficiency of
R&D decisions
•Greater scrutiny in the early
R&D stages
•Integrating health economics
earlier in the process
•Moving some trials to lower
cost locations or using
specialist contract research
organisations to manage
clinical trials
•Alliances/collaborations
Conclusions
40
R&D cost trends per NME are partly the result of strategic behaviour by firms,
including adjustments to changes in requirements for licensing and
marketing, and partly the result of technological change
The R&D Cost of a New Medicine
To enquire about additional information and analyses, please contact Dr.
Jorge Mestre-Ferrandiz at jmestre-ferrandiz@ohe.org
To keep up with the latest news and research, subscribe to our blog, OHE News
Follow us on Twitter @OHENews, LinkedIn and SlideShare
Office of Health Economics (OHE)
Southside, 7th Floor
105 Victoria Street
London SW1E 6QT
United Kingdom
+44 20 7747 8850
www.ohe.org
OHE’s publications may be downloaded free of charge for registered users of its website.
©2013 OHE
41

Mais conteúdo relacionado

Destaque

Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?Office of Health Economics
 
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013Office of Health Economics
 
Bateman eq5dforkingsfundmeeting march2015
Bateman eq5dforkingsfundmeeting march2015Bateman eq5dforkingsfundmeeting march2015
Bateman eq5dforkingsfundmeeting march2015Andrew Bateman
 
Impact of Payer Policies on Pharmaceutical R&D
Impact of Payer Policies on Pharmaceutical R&DImpact of Payer Policies on Pharmaceutical R&D
Impact of Payer Policies on Pharmaceutical R&DOffice of Health Economics
 
EuroQol Agenda and Developing the New EQ-5D-5L Value Sets
EuroQol Agenda and Developing the New EQ-5D-5L Value SetsEuroQol Agenda and Developing the New EQ-5D-5L Value Sets
EuroQol Agenda and Developing the New EQ-5D-5L Value SetsOffice of Health Economics
 
Discussion of presentation by Rachel Baker Perspectives, priorities and plura...
Discussion of presentation by Rachel BakerPerspectives, priorities and plura...Discussion of presentation by Rachel BakerPerspectives, priorities and plura...
Discussion of presentation by Rachel Baker Perspectives, priorities and plura...Office of Health Economics
 
The Distribution of the EQ-5D-5L Index in Patient Populations
The Distribution of the EQ-5D-5L Index in Patient PopulationsThe Distribution of the EQ-5D-5L Index in Patient Populations
The Distribution of the EQ-5D-5L Index in Patient PopulationsOffice of Health Economics
 

Destaque (10)

Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
 
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
 
Bateman eq5dforkingsfundmeeting march2015
Bateman eq5dforkingsfundmeeting march2015Bateman eq5dforkingsfundmeeting march2015
Bateman eq5dforkingsfundmeeting march2015
 
Economic Value of Medical Research
Economic Value of Medical ResearchEconomic Value of Medical Research
Economic Value of Medical Research
 
Perspective, priorities and plurality
Perspective, priorities and pluralityPerspective, priorities and plurality
Perspective, priorities and plurality
 
Impact of Payer Policies on Pharmaceutical R&D
Impact of Payer Policies on Pharmaceutical R&DImpact of Payer Policies on Pharmaceutical R&D
Impact of Payer Policies on Pharmaceutical R&D
 
EuroQol Agenda and Developing the New EQ-5D-5L Value Sets
EuroQol Agenda and Developing the New EQ-5D-5L Value SetsEuroQol Agenda and Developing the New EQ-5D-5L Value Sets
EuroQol Agenda and Developing the New EQ-5D-5L Value Sets
 
Discussion of presentation by Rachel Baker Perspectives, priorities and plura...
Discussion of presentation by Rachel BakerPerspectives, priorities and plura...Discussion of presentation by Rachel BakerPerspectives, priorities and plura...
Discussion of presentation by Rachel Baker Perspectives, priorities and plura...
 
The EQ-5D and Its Use Internationally
The EQ-5D and Its Use InternationallyThe EQ-5D and Its Use Internationally
The EQ-5D and Its Use Internationally
 
The Distribution of the EQ-5D-5L Index in Patient Populations
The Distribution of the EQ-5D-5L Index in Patient PopulationsThe Distribution of the EQ-5D-5L Index in Patient Populations
The Distribution of the EQ-5D-5L Index in Patient Populations
 

Mais de Office of Health Economics

OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOffice of Health Economics
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowseOffice of Health Economics
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isOffice of Health Economics
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Office of Health Economics
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?Office of Health Economics
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleOffice of Health Economics
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeOffice of Health Economics
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMROffice of Health Economics
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Office of Health Economics
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandOffice of Health Economics
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Office of Health Economics
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...Office of Health Economics
 

Mais de Office of Health Economics (20)

Annual lecture
Annual lecture Annual lecture
Annual lecture
 
Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20 Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20
 
Towse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne finalTowse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne final
 
Towse cgd price transparency seminar
Towse cgd price transparency seminarTowse cgd price transparency seminar
Towse cgd price transparency seminar
 
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money is
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to people
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of life
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMR
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in England
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
 

Último

Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 

Último (20)

Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 

R&D Cost of a New Medicine

  • 1. The R&D Cost of a New Medicine Jorge Mestre-Ferrandiz Office of Health Economics University College London • VISION Seminar London • 29 January 2013
  • 2. The R&D Cost of a New Medicine Download or read online at www.ohe.org 2
  • 3. The R&D Cost of a New Medicine 1. Up to date overview of the literature estimating pharmaceutical R&D costs and the factors driving them 2. Present a new estimate from original data of the average R&D cost per new successful medicine Objectives of the OHE Study 3
  • 4. The R&D Cost of a New Medicine Structure of the Book 4 Factors driving R&D costs Mean cost of an NME (S2 & S3) Development times (S2.4) Out-of-pocket costs (S2.2) Success rates (S2.3) Cost of capital (S2.5) Explaining differences from the mean Therapy areas (S4) Compound origin (S5) Firm size (S6) Biologicals (S7) Drivers of Trends in R&D Costs (S8)
  • 5. The R&D Cost of a New Medicine • Published estimates of the mean (average) cost of R&D per new medicine that is launched on the market suggest an increase in cost over the last decade -- from the estimate of US$1.0bn (£600m) by DiMasi et al. (2003), expressed in 2011 price terms, to US$1.9bn (£1.2bn) by Paul et al. 2010) • Our new estimate is US$1.5bn (£900m) and therefore lies between the DiMasi and Paul estimates • Estimates of mean R&D costs per new medicine, and comparisons between such estimates, must be treated with caution: studies differ in both methodology and data used Key Findings 5
  • 6. The R&D Cost of a New Medicine • How much it costs to research and develop a successful new medicine has been an important policy issue at least since the 1960s • Cost estimates matter not just because of intellectual curiosity or for industry understanding of its performance, but because they are a key aspect of the international debate about the reasonableness of pharmaceutical prices and the magnitude of the long- term investments involved • Moreover, a related debate continues about whether the research and development (R&D) productivity of the biopharmaceutical industry has fallen Context 6
  • 7. The R&D Cost of a New Medicine 7 REGULATION TIME (YEARS) PHASES OF DRUG DEVELOPMENT Phase III Development research Final patent application Marketing application Post-mktg research* Phase IV 2002-7 Discovery research Investigational new drug application (US) 1999 Phase I Phase IISynthesis Biological testing & pharmacologic screening 2008 Marketing approval/ product launch 2010 Regulatory review Basic research Short-term animal testing Long-term animal testing Toxicology and pharmacokinetic studies Chemical development Pharmaceutical development Fig 2.1. The R&D Process *Phase IV is not part of the R&D process, although data collected during that time may affect how the drug is used. Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics
  • 8. The R&D Cost of a New Medicine Key Studies 8
  • 9. The R&D Cost of a New Medicine Key Studies 9 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 10. The R&D Cost of a New Medicine • Four main variables determine the capitalised cost of a new drug estimate • Out-of-pocket costs • Success rates • Development times and • Cost of capital Key Components of R&D Costs 10
  • 11. The R&D Cost of a New Medicine Out-of-pocket costs • Out-of-pocket development costs, before adjusting for failures, appear to have increased over time. Similar estimates for total out-of- pocket devel- opment costs but less consistent across clinical trial phases Success rates • Cumulative clinical success rates appear to have decreased over time. The probability is shrinking that a candidate entering Phase I clinical trials will in due course be authorised to be launched onto the market Development times • The total time taken to progress through all phases of clinical trials and market authorisation appears to have remained rela- tively unchanged since the early 2000s Cost of capital • The long time- scales of pharma- ceutical R&D mean that the cost of capital has a major impact on the final cost per drug and so the estimated development cost per successful drug is highly sensitive to the cost of capital applied. An 11% real annual cost is commonly used. Key Components of R&D Costs 11
  • 12. The R&D Cost of a New Medicine • Out-of-pocket development costs, before adjusting for failures, appear to have increased over time since the first DiMasi et al. (1991) article • The most recent estimates, by Paul et al. (2010) and Adams and Brantner (2010), are very similar for out-of- pocket development costs (from Phase I to III) at around US$215-220m (2011 US$) • The studies are less consistent in their estimates of the magnitude of the cost of the different clinical trial phases Out-of-Pocket Costs 12
  • 13. The R&D Cost of a New Medicine Out-of-Pocket Costs 13 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 14. The R&D Cost of a New Medicine • The most recent estimates of probability of success for Phase I, Phase II and Phase III are between 49% and 75%, 30% and 48%, and 50% and 71%, respectively • Overall, cumulative clinical success rates appear to have decreased over time • Pammolli et al. (2011) find significant decreases in success rates, especially in Phases II and III • But analyses by DiMasi and colleagues since the early 1990s suggest that success rates across the different phases have changed little Success Rates 14
  • 15. The R&D Cost of a New Medicine Success Rates 15 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 16. The R&D Cost of a New Medicine • Commercial reasons have been increasingly important for discontinuing projects • Since 2000, companies have been focusing more on high risk, high premium areas with a lower “expected probability of success” (POS), such as: • Chronic diseases (Alzheimer’s disease, diabetes, obesity, rheumatoid arthritis) compared to acute diseases (6.9% vs 8.8%) • Potentially lethal diseases, mostly cancer and some infectious diseases (5.5% vs. 9.7%) [Pammolli, Magazzini and Riccaboni (2011)] Attrition Rates: Reasons for Failure 16
  • 17. The R&D Cost of a New Medicine • Overall, development times (Phases I-III) appear to have remained relatively constant over time, at around 6.5 years (75‒79 months) on average. Phase III trials tend to be the longest development phase, although the most recent work suggests that development times for Phases II and III now are similar Development Times 17
  • 18. The R&D Cost of a New Medicine Development Times 18 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 19. The R&D Cost of a New Medicine • The long timescales of pharmaceutical R&D mean that the cost of capital has a major impact on the final cost per successful drug • The cost of capital should be measured as the expected return that is foregone, i.e. the return that would be expected from investing in an equally risky portfolio of other investments • The estimated cost per successful drug is highly sensitive to the cost of capital applied • The more recent studies use a real annual cost of capital of 11%, up from the 9% used by DiMasi et al. (1991) Cost of Capital 19
  • 20. The R&D Cost of a New Medicine • Two main issues arise with respect to the cost of capital invested in pharmaceutical R&D • The magnitude of the cost of capital • Whether the cost of capital is assumed constant or instead is assumed to fall as an R&D project progresses (if successful) through its various stages from discovery through development to launch – the so-called “staircase” approach Cost of Capital 20
  • 21. The R&D Cost of a New Medicine Cost of Capital 21 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 22. The R&D Cost of a New Medicine Criticisms OHE Book Data – confidential, comes from companies directly and cannot be replicated Other recent studies have either used publicly available information or have used different confidential data (like ours) Only self-originated compounds are included and these represent a small proportion of new drugs – and the most expensive ones Decreasing importance of self-originated compounds relative to licensed-in compounds is valid, but has become so perhaps only recently. More recent estimates cannot differentiate so apply also to a wider universe of compounds, not just self-originated compounds Estimates should not be capitalised, given that companies are not investment houses and have no choice but to spend money on R&D Out-of-pocket costs are merely one part of the total cost. Capitalised costs are real costs. Investors require a return that reflects alternative potential uses of their investment Estimates are pre-tax, so they do not reflect the fact that R&D expenses are deductible Societal perspective when thinking about the costs of R&D of new medicines: total cost of developing a new drug will be the same no matter who pays -- tax rebates affect who bears the costs, but not the total amount Policy Discussions Around the Cost Estimates 22
  • 23. The R&D Cost of a New Medicine • New estimate for mean R&D costs per NME, based on previously unpublished information collected by CMRI in confidential surveys A New Estimate of R&D Costs 23 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 24. The R&D Cost of a New Medicine 24 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 25. The R&D Cost of a New Medicine 25 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 26. The R&D Cost of a New Medicine 26 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 27. The R&D Cost of a New Medicine 27 Source: Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics.
  • 28. The R&D Cost of a New Medicine • Our overall probability of success estimates for Phase I, Phase II and Phase III are lower than those reported by DiMasi et al. (2003) and Paul et al. (2010) • Overall, our study and those by DiMasi et al. (2003) and Paul et al. (2010) report similar development times. For Phase I, our data report the longest development times, but slightly shorter times for Phase III. Phase II times from the CMRI data fall between those reported by DiMasi et al. (2003) and Paul et al. (2010) • Total out-of-pockets costs for Phases I, II and III are very similar in our study and that of Paul et al. (around US$230m at 2011 prices) and slightly lower than found by DiMasi et al (2003). Our out-of- pocket cost estimate lies between the other two estimates for Phase III. For Phase I and Phase II, our estimates are the highest Comparison with Previous Studies 28
  • 29. The R&D Cost of a New Medicine • Published estimates, including ours, that refer to the mean cost of R&D per new medicine are just that: averages • The literature shows that the costs of R&D vary with the subgroup of drugs included in the analysis • Costs vary according to therapeutic area, firm size and whether the molecule is a “traditional” chemical compound or a biologic Warning: Mean Costs May Hide Important Differences 29
  • 30. The R&D Cost of a New Medicine • R&D costs vary substantially across therapeutic areas because of considerable variation in three key variables: success rates, development cycle times and out-of- pocket costs. • The most recent analyses suggest that the most expensive therapeutic areas in terms of drug R&D costs are neurology, respiratory and oncology. This is because drugs in these categories experience lower success rates and longer development times. • By comparison, anti-parasitics and drugs to treat HIV/AIDS have the lowest drug R&D costs because of higher success rates and shorter development times Therapeutic Areas 30
  • 31. The R&D Cost of a New Medicine • Most of the published calculations of R&D costs to date focus on self-originated new compounds because comprehensive data for licensed- in/acquired compounds are very difficult to collect • An increasing proportion of drugs now are licensed in; clinical success rates for such drugs are higher than for self-originated drugs Self-Originated versus Licensed-In 31
  • 32. The R&D Cost of a New Medicine • Greater success may be the results of a “screening effect” for licensed-in compounds: • Many licensed-in drugs already were shown to be promising candidates before licensing • This difference also is apparent during early research Self-Originated versus Licensed-In 32
  • 33. The R&D Cost of a New Medicine • Limited evidence on biological medicines • DiMasi and Grabowski (2007b): overall clinical success rate for biotech products is 30.2%, which is higher than the 21.5% estimate for traditional pharmaceutical products reported by DiMasi et al. (2003) • Total clinical and approval time is 8% longer for biopharma- ceuticals, with nearly all the difference being in Phase I • Capitalisation increases biopharma costs relative to traditional R&D costs because of the longer development timeline and a slightly higher cost of capital Biopharmaceuticals 33
  • 34. The R&D Cost of a New Medicine • Cost of clinical trials • Cost per patient and number of patients • Complexity • Two trends appearing to help control costs • Outsourcing to CROs – increased efficiency • Change in location • Some trials in emerging markets – lower local costs and faster patient recruitment • Still significant proportion of trails located in US and Western Europe – regulatory conditions, relevant expertise and infrastructure Drivers of Trends – Out-of-Pocket Costs 34
  • 35. The R&D Cost of a New Medicine Increase in failure rates • Regulators becoming more risk averse • R&D is directed towards tougher challenges • Within companies, projects may advance prematurely to the later stages of clinical development and then fail in Phase III Reasons to counter increase • Better preclinical screening that ensures earlier project termination • Integrating HTA earlier in the process to encourage earlier decisions about discontinuing projects for commercial reasons • Developing biomarkers and companion diagnostics that can lead to personalised or stratified medicine, with greater prospects for success • Alliances between companies, increasingly common, also may increase success rates Drivers of Trends – Failure Rates 35 In short run important technological challenges may lead to higher failure rates and costs as science advances and while companies learn how to better develop biomarkers and companion diagnostics. But “learning by doing” could drive a more efficient R&D process in the longer term.
  • 36. The R&D Cost of a New Medicine • Regulators may be more risk averse, leading to increased regulatory stringency and longer regulatory reviews • Companies are directing efforts towards therapeutic areas that intrinsically are associated with very long clinical development times • Clinical trials are becoming increasingly complex and, as a result, take longer to complete • Trade offs between time and success rate, e.g. longer Phase II with higher success rate in Phase III Drivers of Trends – Development Times 36
  • 37. The R&D Cost of a New Medicine • Number of alternatives have been put forward to try to make the R&D process more efficient and affordable • The key suggestions include focusing on • The earlier phases reduce technical uncertainties before undertaking the more expensive trials in the later development stages • Allowing for greater flexibility A New Drug Development Paradigm? 37
  • 38. The R&D Cost of a New Medicine Four factors are increasing R&D costs: 1. Higher out-of-pocket costs, up nearly 600% from the 1970s to the 2000s 2. Lower success rates for clinical development as tougher therapeutic areas are tackled—e.g. neurology (Alzheimer’s), autoimmune diseases (arthritis), and oncology—from 1 in 5 in the 1980s to 1 in 10 in the 2000s 3. Increases in R&D times as both regulation and science have become more complex, from 6 years in the 1970s to 13.5 years in the 2000s 4. Increases in the cost of capital—i.e. providing returns to funders that reflect the high risk of investing in medicines R&D—from 8% in the 1970s to 11% in the 2000s Conclusions 38
  • 39. The R&D Cost of a New Medicine • Important variations around the mean cost per NME for different types of medicines are observable • Significant differences are evident in the cost of R&D for new medicines across therapeutic areas – can be more than twofold • Licensed-in compounds tend to be more successful than self- originated NMEs • Drugs with a more validated target and more objective endpoints are more successful than drugs with more novel mechanisms of action and less clear cut endpoints • Total capitalised costs for biologics appear to be higher than for other pharmaceuticals Conclusions 39
  • 40. The R&D Cost of a New Medicine Technological challenges •Targeted diseases currently are more complex •Companies need to adapt to new personalised/stratified medicines environment Firms’ behaviour •Companies continue to work to improve the efficiency of R&D decisions •Greater scrutiny in the early R&D stages •Integrating health economics earlier in the process •Moving some trials to lower cost locations or using specialist contract research organisations to manage clinical trials •Alliances/collaborations Conclusions 40 R&D cost trends per NME are partly the result of strategic behaviour by firms, including adjustments to changes in requirements for licensing and marketing, and partly the result of technological change
  • 41. The R&D Cost of a New Medicine To enquire about additional information and analyses, please contact Dr. Jorge Mestre-Ferrandiz at jmestre-ferrandiz@ohe.org To keep up with the latest news and research, subscribe to our blog, OHE News Follow us on Twitter @OHENews, LinkedIn and SlideShare Office of Health Economics (OHE) Southside, 7th Floor 105 Victoria Street London SW1E 6QT United Kingdom +44 20 7747 8850 www.ohe.org OHE’s publications may be downloaded free of charge for registered users of its website. ©2013 OHE 41